Human T-lymphotropic virus type 1 (HTLV-1) is a complex retrovirus that encodes typical gag, pol, and env gene products as well as unique regulatory and accessory genes (11) . HTLV-1 causes adult T-cell leukemia/lymphoma (ATL) and is etiologically linked to tropical spastic paraparesis/HTLV-associated myelopathy (HAM/TSP), a chronic neurodegenerative disorder (12, 21) , as well as a variety of other immune-mediated diseases (10) . The role of HTLV-1 in mediating these diseases is not clear but is likely related to the ability of the virus to evoke lymphocyte activation (14) . The complex genome of HTLV-1 contains unique regulatory and accessory genes in four open reading frames (ORFs), I to IV, of the pX region. ORFs IV and III of HTLV-1 encode the well-characterized Tax and Rex proteins, respectively. Tax is a 40-kDa nucleuslocalizing phosphoprotein which increases viral transcription from the HTLV-1 long terminal repeat (LTR) as well as many cellular genes involved in host cell proliferation (19) . Rex is a 27-kDa nucleolus-localizing phosphoprotein that increases the cytoplasmic accumulation of nonspliced and singly spliced viral RNA (13) .
In contrast to the extensive knowledge of Tax and Rex structure and function, little is known about the role of pX ORF I and ORF II in the replication or pathogenesis of HTLV-1. However, emerging evidence supports the expression of pX ORFs I and II both in vitro and in vivo and the importance of these conserved ORFs in the replication of HTLV-1. At least eight alternatively spliced mRNAs are expressed from the 3Ј or pX region of HTLV-1 (2) . Reverse transcription-PCR assays identified mRNAs from infected cell lines and freshly isolated cells from HTLV-1-infected subjects (17) . Cereseto et al. (3) reported the detection of the same RNA species from patients with ATL and HAM/TSP using a semiquantitative RNase protection assay. Importantly, cytotoxic CD8 ϩ T cells from HTLV-1-infected individuals have recently been demonstrated to recognize pX ORF I-and II-derived peptides, indicating that these viral proteins are expressed in vivo (22) . Despite evidence for the expression of pX ORF I and ORF II, these viral genes do not appear to be required for viral infectivity, replication, or transformation in typical cell culture systems. In contrast, using an infectious molecular clone of HTLV-1 (7) with selective mutations that ablated the mRNA from ORF I (encoding p12 I ), we were the first to identify a functional role of pX ORF I in establishment of infection in an animal model (6) .
ORF II is spliced to the first tax exon and encodes two proteins, a full-length p30 II and an internally initiated p13 II . The smaller protein, p13 II , is derived from initiation at the first internal methionine codon in ORF II and represents the carboxyl-terminal 87 residues of p30 II . The p30 II and p13 II proteins were initially found to localize to the nucleolus and nucleus, respectively (16) , but p13
II also localizes to mitochondrial membranes (5) . The cellular segregation of ORF II gene products suggests specific roles for these proteins in the regulation of HTLV-1 expression or as mediators of virus-cell interactions. The p30 II protein contains serine-and threonine-rich regions with distant homology to transcription factors Oct-1 and -2, Pit-1, and POU-M1 (4). We have recently reported that mutations in the ACH.p30 II /p13 II viral clone which destroy the initiator methionine of the mRNA encoding p13 II and insert an artificial termination codon in the mRNA encoding p30 II prevent the virus from obtaining normal levels in rabbits (1) .
In this study, we have tested the transcriptional ability of p30 II in mammalian cells by using a yeast Gal4 fusion protein system and transfection of luciferase reporter genes driven by CREB-responsive promoters. Our data indicate that p30 II , as a Gal4 fusion protein, significantly transactivates Gal4-driven luciferase reporter gene activity in multiple cell types. Furthermore, we provide data demonstrating that the transcriptional activity of p30 II -Gal4 DNA-binding domain (DBD) (DBD) is independent of TATA box flanking sequences by comparing two different Gal4 reporter systems. Mutational studies of p30 II indicated that the transactivation domains reside within the central portion of the protein (between amino acids 62 and 220). Interestingly, small amounts of p30 II expression transactivated HTLV-1 LTR-driven reporter gene activity, even in the presence of Tax, whereas higher concentrations repressed LTR and CRE-driven reporter gene activity. Our data provide the first evidence to support the transcriptional activity of p30 II and suggest an important role for the nuclear protein in HTLV-1 replication and cellular gene expression. were grown in 10-cm tissue culture dishes in Dulbecco's minimal essential medium (DMEM) containing 10% fetal bovine serum and 1% streptomycin and penicillin at 37°C. Cells were split and cultured in six-well plates to 50% confluence 16 h before transfection according to the manufacturer's protocol (Lipofectamine-Plus; Gibco-BRL).
MATERIALS AND METHODS

Cell
Gal4-mediated transcription assay. (i) Reporter plasmids. Plasmid p5XGT-TATA-Luc, a kind gift of P. Quinn (The Pennsylvania State University, Hershey, Pa.), contains five tandem Gal4 DNA-binding sequences upstream of a TATA box, derived from positions Ϫ64 to ϩ1 of the phosphoenolpyruvate carboxykinase (PEPCK) gene in a luciferase reporter gene plasmid (25) . pGL2-TATA-Luc was constructed by ligating the TATA box of the adenovirus E1b gene, derived from plasmid E1b-CAT (24) , into the XhoI and BglII sites of pGL2-basic, a luciferase reporter gene vector (Promega), and then subcloning tandem copies of Gal4 DNA-binding sequence using KpnI and XhoI sites.
(ii) Effector plasmids. The p30 II -Gal4(DBD) expression vector was constructed by replacing the CREB-(1-247)-encoding sequence of CREB-Gal4-pCRG4-11 (a kind gift of P. Quinn, The Pennsylvania State University) with the p30 II -encoding sequence synthesized by PCR amplification with 5Ј primer 5Ј-A [ATATGAATTCATGGCACTATGCTGTTCGCC) and 3Ј primer 3Ј-A (TATA ACTAGTTTAGAGGTTCTCGGGTG) from the HTLV-1 molecular clone ACH (15) , including 5Ј EcoRI and 3Ј SpeI restriction sites (underlined). Similarly, all truncated mutants (MT-1 through MT-6) of the p30 II expression vector were constructed by replacing CREB-(1-247)-encoding sequence of CREBGal4-pCRG4-11 (containing Gal4-DBD) with appropriate truncated p30 II -encoding sequences synthesized by PCR from ACH using the following primers: for MT-1, p30
II (1-220) 5Ј-A (above) and TATAACTAGTGGGCACCAGTCGCC TTGT (3Ј-B); for MT-2, p30 II (1-179) 5Ј-A and TATAACTAGTGGTTAACTT TGTATCTGT (3Ј-C); for MT-3, p30
II (1-132) 5Ј-A and TATAACTAGTGGA AGAGTTAAAGGACAA (3Ј-D); for MT-4, p30 II (1-62) 5Ј-A and TATAACT AGTGCGGGAGAAAGAGGAGGA (3Ј-E); for p30 II (62-220) ATATG AATTCATGTCTTTTTTTCGCTTCCTC (5Ј-B) and 3Ј-B; for p30 II (179-241) ATATGAATTCATGCTTATTATCAGCCCA (5Ј-C) and 3Ј-A (above).
All of the inserted p30 gene sequences were in frame and had similar expression efficiencies, which was verified by immunoblot assay of transfected HeLa-tat cells. The p30 II -HA expression vector (pCMV-p30 II -HA) was a kind gift of G. Franchini (National Cancer Institute, Bethesda, Md.) (16) .
(iii) Gal4 transcription assay. For each trial, 0.3 g of reporter plasmids (p5XGT-TATA-Luc and pGL2-TATA-Luc) and 0 to 1.5 g of effector plasmids (p30 II -Gal4-pCRG4-11, pCMV-p30 II -HA, and Gal4-pCRG4-11) were transfected as indicated in figure legends. As an internal control for transfection efficiency, 0.1 g of pRSV-␤-gal (P. Quinn, The Pennsylvania State University) was also used in each transfection. pBlue-Script (Stratagene) was used as carrier DNA to equalize DNA concentrations for each transfection. Transfected cells were lysed with 1ϫ lysis buffer (Promega) using 0.5 ml/well at room temperature for 15 min. Twenty microliters of each lysate was used to test luciferase reporter gene activity using an enhanced luciferase assay kit (Promega) according to the manufacturer's protocol. To normalize transfection experiments, 5 l of each lysate was assayed for ␤-galactosidase activity according to the manufacturer's protocol (Lumigen, Southfield, Mich.). Results were expressed as mean fold increase Ϯ standard deviation (SD) in arbitrary light units of luciferase activity in four independent trials for each set of experiments. Statistical comparisons of data sets were performed by a standard two-sample t test.
CRE-and TRE-mediated transcription assay. pCRE-␣-Luc, a kind gift of S. McKnight (University of Washington), has a promoter with three repeats of the CRE element within the sequences from Ϫ168 to ϩ45 of the ␣-subunit of the human glycoprotein hormone gene (18) . The HTLV-1 LTR-Luc plasmid is driven by the complete HTLV-1 LTR, which has three repeats of the Taxresponsive element (TRE), and was constructed by cloning the LTR sequence of HTLV-1 into pGL2-basic vector (20) . The p30 II -HA expression vector (pCMVp30 II -HA) is described above (Gal4 assay). The HTLV-1 Tax expression vector (pCMV-Tax) has been described previously (20) . For each transfection, 0.3 g of reporter plasmids (pCRE-␣-Luc and pLTR-Luc) and 0 to 1.0 g of effector plasmids (pCMV-p30 II -HA and pCMV-Tax) as indicated in the figure legends were used for each transfection. As an internal control for transfection efficiency, 0.1 g of pRSV-␤-gal was also used in each transfection. pBlue-Script (Stratagene) was used as carrier DNA to equalize DNA concentrations for each transfection. Luciferase activity and transfection control methods were the same as in the Gal4 transcription assay above.
Preparation of nuclear extracts. Nuclear extracts were prepared by a modification of the method previously described by Dignam et al. (9) . Briefly, 10 6 transfected cells were washed twice with ice-cold phosphate-buffered saline (PBS), harvested in 5 ml of PBS, and centrifuged at 400 ϫ g for 5 min at 4°C. The pellet was washed with 4 packed cell volumes of hypertonic buffer containing 10 mM Tris-HCl (pH 7.8), 1.5 mM MgCl 2 , and 10 mM KCl and left on ice for 10 min. The cells were then lysed by 10 strokes of a Dounce homogenizer using a type B pestle. The presence of intact cell nuclei was determined by cytospin analysis. Intact nuclei were sedimented at 4,500 ϫ g for 5 min at 4°C, resuspended in 2 packed cell volumes of hypotonic buffer containing 420 mM KCl, 20 mM Tris-HCl (pH 7.8), 1.5 mM MgCl 2 , and 20% glycerol, and incubated at 4°C with gentle agitation for 1 h. Immediately before use, 0.5 mM dithiothreitol (DTT), 0.4 mM phenylmethylsulfonyl fluoride (PMSF), 10 g of microcystin, and 2 g each of leupeptin and pepstatin per ml were added fresh to the nucleus preparation buffer. After complete lysis of nuclei, the nuclear extract was centrifuged at 10,000 ϫ g for 30 min at 4°C. The supernatant was dialyzed twice against 500 ml of dialysis buffer containing 20 mM Tris-HCl (pH 7.8), 100 mM KCl, 0.2 mM EDTA, and 20% glycerol for 4 h at 4°C. The nuclear lysate then was aliquoted and frozen in liquid N 2 immediately and stored at Ϫ80°C. A mouse monoclonal antibody that recognizes the 27-kDa Fas-associated death domain protein (Transduction Labs) and a rabbit polyclonal antibody that recognizes histone H1 (Upstate Biotechnology) were used to verify cytoplasmic and nuclear fractions, respectively, by Western immunoblot assay.
Expression of p30 II proteins. HeLa-tat cells at approximately 65% confluence in 10-cm tissue culture dishes were transfected using calcium phosphate with 10 g of pCMV-p30 II -HA, p30 II -Gal4-pCRG4-11, or p30 II -mutant-Gal4-pCRG4-11 plasmids MT-1 through MT-6. At 48 h posttransfection, the nuclei and cytosol of transfected cells were prepared as described above. Whole cell lysates were made by lysis of cells (90% confluent in 10-cm dish) using 0.4 ml of radioimmunoprecipitation buffer (1ϫ PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) containing 1 mM PMSF, 2 g of aprotinin, 2 g of pepstatin A, and 1 g of leupeptin per ml. Each 50 g of nuclear, cytosolic, and whole-cell lysates was electrophoresed by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose membrane (Millipore), blocked using 5% nonfat milk in 1ϫ Tris buffer (0.5 M Tris-HCl [pH 7.5], 1.5 M NaCl, 0.1% NP-40) for 1 h at 4°C. The blocked membrane was incubated with primary polyclonal anti-HA serum (Santa Cruz Biotechnology) or polyclonal anti-Gal(DBD) serum (Santa Cruz) (each 1:1,000 in Tris buffer containing 3% bovine serum albumin) overnight at 4°C. After extensively washing the membrane with Tris-Tween buffer solution (TTBS; 0.5 M Tris-HCl [pH 7.5], 1.5 M NaCl, 0.075% Tween 20) the membrane was blotted with anti-rabbit antibody serum (1:1,000 in TTBS containing 5% nonfat dry milk) for 1 h at room temperature. After washing the membrane three times with TTBS, the membrane was developed using enhanced chemiluminescence and exposed to film according to the manufacturer's protocols (Amersham).
To detect p30 II by immunofluorescence, HeLa-tat cells were seeded in chamber slides (Fisher Scientific) at approximately 40% confluence 18 h prior to transfection. Transfection with 4 g of pCMV-p30 II -HA was performed using Lipofectamine plus (Sigma). At 48 h posttransfection, DMEM was removed and cells were washed twice in PBS. Fixation of the cells for 15 min using 4% paraformaldehyde was performed at room temperature. Cells were then incubated with a monoclonal anti-HA antiserum (Babco) overnight at 4°C, followed by incubation with indocarbocyanine-labeled anti-mouse immunoglobulin (Jackson Immunogen) for 1 h at room temperature. The expression of p30 II -HA was evaluated by immunofluorescence microscopy (Zeiss Axioplan2 II -Gal4(DBD) expression vector (10 g/10-cm dish) were prepared as described above. Tandem copies of Gal4 DNA-binding sequence (CGGAGGACTCGTCTCCG) were synthesized and used as the probe in the EMSA. The probe was 32 P labeled using T4 kinase (Promega) at 37°C for 30 min. The 32 P-labeled 2ϫ Gal4-DNA-binding sequence oligonucleotide was separated from free [ 32 P]ATP by a Sephedex G50 filtration column (Amersham). Binding was performed in 30 l of binding reaction buffer containing 20 mM Tris, 1 mM MgCl, 12% glycerol, 0.1 mM DTT, 10 to 15 g of nuclear protein, and 1 g of poly(dI-dC) (Pharmacia). Various concentrations of unlabeled Gal4-DNA-binding sequence oligonucleotide were used as a specific competitor of probe. Specific antiserum (2 g) for Gal4(DBD) (Santa Cruz) was added to the binding reaction mixture for the supershift assay. After 25 min of incubation at 4°C, 0.5 to 1.0 ng (20,000 to 40,000 cpm) of 32 P-labeled 2ϫ Gal4(DBD) oligonucleotide probe was added to each reaction and further incubated for 30 min at 25°C. The sample was electrophoresed in 5% nondenatured polyacrylamide gels in 0.5ϫ Tris-borate-EDTA at a constant 180 V for 4 h at 4°C. The gel was subsequently dried, and bands were visualized by autoradiography.
RESULTS
HTLV-1 p30
II localizes to the nucleus. Nuclear localization or conditional translocation to the nucleus is a characteristic of most proteins that function as a transcription factor. Previous studies have demonstrated by standard immunofluorescence methods that HTLV-1 p30 II was localized in the nucleolus of transfected cells and contained two nuclear localization signals (16) . Consistent with previous reports, p30 II was detected predominantly in the nuclear fraction of our transiently transfected HeLa-tat cells by immunoblot assay (Fig. 1A) . We verified these results using an immunofluorescence assay (Fig.  1B) II has several important structural characteristics of a transcription factor, including nuclear localization sequences, serine/threonine-rich motifs, and regional homology with the transcription factor Oct-1 in DNA-binding regions. While these observations suggest that p30 II 
II could influence transcription, we used a Gal4 system and constructed p30
II as a chimeric protein with the DBD of Gal4. The Gal4(DBD) (amino acids 1 to 147) was cloned into the carboxyl-terminal region of full-length p30 II (amino acids 1 to 241) to form the p30 II -Gal4(DBD) expression vector (p30 II -Gal4-pCRG4-11) ( Fig. 2A) . We initially tested a reporter construct, p5XGT-TATA-Luc, whose promoter contains five copies of the Gal4 DNA-binding site upstream of the TATA box derived from the PEPCK promoter (Ϫ61 to ϩ1) ( Fig. 2A) . As expected, cotransfection of the parent Gal4-pCRG4-11 vector with p5XGT-TATA-Luc resulted in no significant luciferase reporter gene activity (Fig.  2B) . In contrast, in a dose-dependent manner, p30 II -Gal4-pCRG4-11 elicited up to an 18-fold mean increase in reporter gene activity (Fig. 2B) . The fact that p30 II in the absence of Gal4(DBD) did not significantly promote reporter gene activity indicates a requirement for localization of p30 II to the Gal4 promoter (Fig. 2B) .
To test whether the observed transactivation of reporter gene activity by p30
II -Gal4-pCRG4-11 was dependent on specific flanking sequences adjacent to the TATA box region, the p5XGT-TATA-Luc containing the TATA box from the PEPCK (Ϫ61 to ϩ1) gene promoter was compared with pGL2-TATA-Luc. pGL2-TATA-Luc contains a minimal TATA box derived from the E1b gene promoter of adenovirus. Both luciferase reporter gene activities were significantly increased (up to 18-to 25-fold) by cotransfection with the p30 II -Gal4-pCRG4-11 expression vector (Fig. 2C) . These data indicate that transactivation of reporter gene activity by p30
II is independent of the flanking sequence of the TATA box. We confirmed the transcriptional activity of p30 II in a dose-dependent manner using 293 cells (Fig. 2D) .
p30 II -Gal4(DBD) binds to the Gal4 promoter in a dosedependent manner. To test if p30
II -Gal4(DBD) bound the Gal4 promoter directly, we quantitatively analyzed the promoter-binding activity of p30 II -Gal4(DBD) fusion protein in transfected HeLa-tat cells by EMSA. p30 II -Gal4(DBD) in nuclear lysates of HeLa-tat cells bound to Gal4-DNA-binding sequences efficiently and in a dose-dependent manner (Fig. 3) . Nuclear proteins (50 to 250 ng) from HeLa-tat cells transfected with 10 g of p30 II -Gal4-pCRG4-11 plasmid for 48 h bound to only one site of the double Gal4-DNA-binding probe (site 1), which resulted in a single shifted band (Fig. 3A, lanes 2 to 6,  band 1 ). Higher concentrations of nuclear lysates (300 to 350 ng) containing p30 II -Gal4(DBD) elicited an additional band corresponding to binding of a second binding site by p30 II -Gal4(DBD) (Fig. 3A, lanes 7 and 8, band 2) . When the nuclear proteins were further increased to 400 ng, both Gal4-DNAbinding sites of the probe were occupied, which resulted in a II -HA for 48 h as described in the text. Twenty-five micrograms of cellular extract was separated in SDS-10% PAGE gels and blotted on nitrocellulose membranes. p30 II -HA was detected by immunoblot analysis using polyclonal rabbit anti-HA serum. A mouse monoclonal antibody that recognizes the 27-kDa Fas-associated death domain protein (FADD; Transduction Labs) and a rabbit polyclonal antibody that recognizes histone H1 (Upstate Biotechnology) were used to verify cytoplasmic and nuclear fractions, respectively.
(B) Light microscopic (LM) and immunofluorescence assay (IMF) of HeLa-tat cells 48 h after transfection with 4 g of pCMV-p30
II -HA as described in the text. p30 II -HA expression in cell nuclei was detected using a monoclonal anti-HA antiserum by indirect immunofluorescence assay (Zeiss Axioplan2) and stored from the same microscopic field as photomicrographs using a digital camera (Diagnostic Instruments Inc.). predominant and slower migrating band 2 (Fig. 3A, lane 9) . The addition of Gal4(DBD)-specific antiserum resulted in a supershifted band (Fig. 3A, lane 10, band 3) . In addition, when a 10-to 30-fold excess of nonlabeled Gal4-DNA-binding oligonucleotides were added as competitors to the binding reaction, the shifted bands were efficiently attenuated (Fig. 3A,  lanes 11 and 12) . Figure 3B illustrates the EMSA band shifts. Collectively, these data indicated that the observed shifted probe bands were p30 II -Gal4(DBD) specific and provided direct evidence to show the specific interactions between Gal4(DBD)-containing p30
II and the promoter of the Gal4 reporter gene.
Mutation of p30 II reveals a central core that mediates transcriptional activity. In order to determine the structural motifs of p30
II that mediated the transcriptional activity in our Gal4 system, a series of six truncated p30 II mutants were fused to Gal4(DBD). These mutants of p30 II contained progressive deletions in both the amino-and carboxyl-terminal regions of the protein (Fig. 4A) . Each of the p30 II mutant proteins was expressed at the expected molecular weight, as indicated by immunoblot analysis (Fig. 4B) . Equal amounts of wild-type p30 IIGal4(DBD) and each of the mutant proteins were evaluated by cotransfection with our p5XGT-TATA-Luc reporter gene plasmid in HeLa-tat cells. The luciferase activity elicited by p30 II -Gal4(DBD) was compared to luciferase activity elicited by each of the six p30 II -Gal4(DBD) mutants (Fig. 4C ). Luciferase activity elicited by the serially deleted mutants MT-1 through MT-4 was progressively reduced compared to wildtype p30 II -Gal4(DBD) (from 75% to less than 10% of wildtype levels). These data indicate that the amino acid sequence from 62 to 220 of p30 II is essential for the transcriptional activity observed in our assays. This observation was further confirmed by mutant MT-5, which represents the central amino acid sequence from 62 to 220 of p30 II , which retained 85% of the transactivation of wild-type p30 II II transcriptional activity in the context of the HTLV-1 promoter, we compared the ability of p30 II expressed from a pCMV-p30 II -HA expression plasmid to mediate CRE-and TRE-mediated reporter gene activity. Because of the known importance of HTLV-1 Tax in the regulation of these promoter elements, we tested each of our reporter gene systems with simultaneous Tax expression in a dose-dependent manner. Cotransfection of pCMV-Tax consistently increased the basal luciferase activity of both reporter gene constructs from 15-to 25-fold (Fig. 5A) . The pCMVp30 II -HA plasmid was cotransfected into 293 cells with the CRE-and TRE-luciferase reporter plasmids in the absence and in the presence of Tax (pCMV-Tax). p30
II repressed the cellular CRE-driven reporter gene activity in a dose-dependent manner (Fig. 5B) and also reduced the positive transcriptional effects of Tax (Fig. 5C) . Interestingly, lower concentrations of the p30 II plasmid (Ͻ0.1 g) consistently activated HTLV-1 LTR reporter gene activity, but increased amounts (Ͼ0.1 g) of the plasmid repressed LTR reporter gene activity (Fig. 5B) . Tax expression only modestly influenced this differential pattern of p30 II effects on LTR-mediated transcription, and the positive effect of lower concentrations of p30 II in LTR-mediated reporter gene activity were additive to typical Tax effects (Fig. 5C) . Cotransfection of pCMV-p30 II -HA had no effect on expression of pRSV-␤-gal (data not shown). These data suggest that low concentrations of p30 II have the potential to differentially interfere with the transcription of CRE-driven gene activity while promoting LTR-mediated transcription.
DISCUSSION
Our data are the first to demonstrate the functional role of p30 II in modulating transcription. Using a yeast Gal4 fusion protein system and transfection of luciferase reporter genes driven by CREB-responsive promoters, we provide evidence to support the ability of p30 II to serve as a transcription factor in mammalian cells. Transcriptional activity of the nucleus-localizing p30 II -Gal4(DBD) was independent of TATA box flanking sequences, and selected mutant proteins indicate that the transactivation domains of p30 II are localized between amino acids 62 and 220. Furthermore, we demonstrated that p30 cally influence the ability of the proviral clone ACH to maintain proviral loads in infected rabbits (1) . Furthermore, Pique et al. (22) have recently reported that cytotoxic CD8 ϩ T cells from HTLV-1-infected individuals recognize pX ORF I-and II-derived peptides, indicating that these viral proteins are expressed in vivo.
HTLV-1 p30 II (also referred to as Tof) contains several important features of many transcription factors. The protein contains a region rich in serine and threonine residues, which are conserved in the transcriptionally important domains of several octamer-binding transcription factors such as Oct-1, Oct-2, and Pit-1. In addition, p30 II has nuclear localization signal sequences. These features imply that p30 II functions as a transcription factor in HTLV-1-infected cells. Our data suggest that the enhancement of Gal4 reporter gene activity by p30 II -Gal4(DBD) specifically results from the interactions between p30
II and the transcription complex bound to or associated with the transcription start site. To further define the molecular mechanism of p30 II -mediated transactivation, it will be important to identify binding proteins for p30
II among the transcription machinery complex.
The results from our p30 II mutant studies indicated that the on October 1, 2017 by guest http://jvi.asm.org/ transactivation motif of p30 II was localized in the middle region of the protein (residues 62 to 220). This core region includes the defined nuclear localization signal and serine/ threonine-rich regions (4). We found that p30 II -Gal4(DBD) mutants with progressive deletions in the C-terminal sequences of p30 II (from MT-1 to MT-4) correspondingly lost their ability to mediate transcription. MT-4, representing only the first 62 amino acids of the N terminus, lost almost all of its ability to mediate transcription. Our conclusions are further supported by data from the evaluation of MT-5 (62 to 220), which retained the ability to promote reporter gene activity nearly as efficiently as wild-type p30 II despite the fact it lacks N-terminal (1 to 62) and C-terminal (220 to 241) sequences. MT-6 (retaining sequences corresponding to p13 II ) lost as much as 75% of the transactivation of reporter gene activity, suggesting that p13 II serves a different role in the viral life cycle (5) . Further studies using site-directed mutations are needed to define the particular amino acid residues of p30 II that serve as the transactivation domain of the protein.
Our data showing that p30 II differentially influences CREand TRE-driven reporter gene activity are not without precedence. Similarly, the regulation of the immediate-early (IE) gene promoter of herpes simplex virus type 1 (HSV-1) is dependent on the interplay between cellular and viral transcription factors. VP16, a potent transcription factor from HSV-1, binds the host cell protein HCF, which allows the viral protein to form a stable complex with Oct-1 (29) . The IE gene promoter contains an Oct-1-like motif (TAATGARAT) that is critical for IE gene expression. Cellular octamer-binding proteins can mediate the inhibition of IE promoters. The TAAT GARAT motif (where R is a purine) has been demonstrated to cause both positive and negative effects, depending on the context of these cellular transcription factors and VP16 (27) . As a result, these motifs have been postulated to mediate active transcription of HSV-1 during lytic cycles of replication but silence the IE genes during HSV-1 latency by serving as a target for inhibitory octamer-binding proteins. HTLV-1 p30 II -HA had no effect on expression of pRSV-␤-gal, used as a transfection control. Results are expressed as mean percent change in arbitrary light units (ALU) Ϯ SD in luciferase activity for four independent trials. had no positive influence on LTR-Tax reporter gene activity (4) . However, this study did not report the concentrations of expression plasmids used to monitor LTR-mediated reporter gene activity or whether p30
II was tested in a dose-dependent manner. Our data indicate that the transcriptional effects of p30 II on LTR reporter gene activity are concentration dependent. In context to the infected cell, in which small amounts of p30 II are likely to be expressed, this viral protein may successfully promote viral transcription while suppressing basal CREmediated gene expression.
In summary, this report provides the first evidence that p30 II mediates transcriptional activity. We believe that p30 II functions in infected cells as either a transcriptional activator or repressor, depending on the cis-acting sequence of the promoter and p30 II expression levels. Further studies are required to identify DNA or protein targets that form functional partners with p30
II before the role of the viral protein is delineated in context to the replication of HTLV-1 or in mediating the pathogenesis of virus-associated diseases.
